Gilead Sciences had a strong Q1 performance highlighted by positive news on HIV drug

From Yahoo Finance: 2025-04-09 08:50:00

ClearBridge Investments released its Q1 2025 investor letter, underperforming its benchmark due to detractors in energy and financials. The strategy saw contributions from overweight in energy and underweight in IT. Gilead Sciences, Inc. (NASDAQ:GILD) was highlighted as a top performer in the healthcare sector. The stock had a one-month return of -9.47% and closed at $103.19 on April 8, 2025.

In the investor letter, ClearBridge Value Strategy praised Gilead Sciences, Inc. (NASDAQ:GILD) for strong fourth-quarter earnings growth and positive news on its HIV prevention treatment drug Lenacapavir. The stock gained 51.48% over the last 52 weeks. Despite this, Gilead Sciences, Inc. (NASDAQ:GILD) is not among the 30 most popular stocks among hedge funds, with 74 portfolios holding it at the end of Q4 2024. Some investors prefer AI stocks for higher returns in a shorter timeframe.

Gilead Sciences, Inc. (NASDAQ:GILD) was featured in another article on undervalued biotech stocks to invest in. The company’s potential is acknowledged, but some investors see more promise in AI stocks for higher returns. For more investor insights, check out hedge fund investor letters for Q1 2025.



Read more at Yahoo Finance: Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1